APD668 是一种有效的,选择性和具有口服活性的 G 蛋白偶联受体GPR119激动剂,对hGPR119和rGPR119的EC50值分别为 2.7 nM 和 33 nM。APD668 对除CYP2C9(Ki=0.1 μM) 以外的五种主要 CYP 亚型均无明显抑制作用。APD668 可用于脂肪性肝炎和糖尿病的研究。
生物活性 | APD668 is a potent, selective and orally active agonist ofG-protein coupled receptorGPR119, withEC50s of 2.7 nM and 33 nM forhGPR119andrGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception ofCYP2C9(Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes[1][2]. |
IC50& Target | CYP2C9 0.1 μM (Ki) | hGPR119 2.7 nM (IC50) | rGPR119 33 nM (IC50) | hERG channel 3 μM (IC50) |
|
体外研究 (In Vitro) | APD668 increases adenylate cyclase activation in HEK293 cells transfected with human GPR119 in a concentration-dependent manner with an EC50of 23 nM[1]. APD668 is highly bound to plasma proteins of male and female cynomolgus monkeys and humans (?99%), but is less extensively bound to male (93.0%) and female (96.6%) rats[1].
|
体内研究 (In Vivo) | APD668 (10-30 mg/kg; p.o. once daily for 8 weeks) significantly reduces blood glucose and glycated hemoglobin (HbA1c) levels, with no desensitization of the acute drug response[1]. APD668 (1-10 mg/kg; a single p.o.) markedly reduces blood glucose levels during oral glucose tolerance test in a dose-dependent manner in mice[1]. APD668 (0.08 mg/kg/min; i.v.) shows no effect during euglycemic condition, but significantly stimulates insulin release when blood glucose levels are raised to approximately 300 mg/dl in a hyperglycemic clamp model in the Sprague-Dawley rat[1]. APD668 (p.o.) exhibits rapid to moderate absorption (tmax≤2 h) in mice, rats, and monkeys, but slower in dogs (tmax=6 h), and moderate to good absolute oral bioavailability (44-79%) in mice, rats, and monkeys, but lower in dogs (22%)[1].
Animal Model: | Male Zucker Diabetic Fatty (ZDF) rats (6 weeks old, 200-250 g)[1] | Dosage: | 10, 30 mg/kg | Administration: | P.o. once daily for 8 weeks | Result: | Decreased the blood glucose and HbA1c levels at 30 mg/kg/day. Did not develop diabetes, whereas the vehicle treated rats did. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 33.33 mg/mL(69.80 mM;Need ultrasonic) 配制储备液 1 mM | 2.0942 mL | 10.4710 mL | 20.9420 mL | 5 mM | 0.4188 mL | 2.0942 mL | 4.1884 mL | 10 mM | 0.2094 mL | 1.0471 mL | 2.0942 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.36 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.36 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。
*以上所有助溶剂都可在本网站选购。 |